IGMS: IGM Biosciences Inc. Price to Sales
High profitability at IGM Biosciences, Inc. (IGMS) is supported by laboratory diversification and streamlined cold-chain logistics. The market capitalization-to-revenue ratio clearly demonstrates the business valuation, where the metric stands at 0.30. A team of top biologists is creating future pharmaceuticals based on a unique engineering platform. Independence from macroeconomic fluctuations transforms these innovative developments into a reliable defensive asset.
IGM Biosciences, Inc. (IGMS) - metric breakdowns and financial figures
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio IGM Biosciences, Inc.|IGMS - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital igmbio.com|IGMS - Company Aggregate Debts|Debt to Book Capitalization Ratio IGM Bio|IGMS - Company Long-Term Debts|Short-Term Debt Volume IGM Biosciences|Immediate Liquidity igmbio.com
- net income and valuation ratios data:
IGMS - Company Net Income|Company Profit Forecast IGM Biosciences, Inc.|IGMS - P/E Multiple|Projected Price to Earnings igmbio.com|IGMS - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio IGM Bio|IGMS - Operating profit EBITDA|Net earnings per one share for the last twelve months IGM Biosciences|IGMS - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months igmbio.com|IGMS - Earnings growth in current year|Expected earnings per share growth for next year IGM Biosciences, Inc.
- issuer revenue and sales details:
General company analysis:IGM Biosciences Inc. IGMS
For IGM Biosciences, Inc. (IGMS), assessing market value through the lens of revenue allows for a correlation between capitalization and the commercialization efficiency of biologics, which require complex cold-chain logistics to maintain antibody activity. By analyzing the price/sales ratio, an investor can see the relationship between the market price and sales volume, which helps quickly identify fundamental growth drivers and avoid overpaying for future expectations during valuation peaks.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|Price-to-Revenue Coefficient Protagonist Corp PTGX|IMVT: P/S Multiple|Price-to-Revenue Multiple kiniksa.com KNSA|Price-to-Revenue Ratio Grifols|Market Cap to Revenue Adaptive Biotech (ADPT)|Market Cap to Revenue CLDX (Celldex)|AUPH (Aurinia Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple BCRX (BioCryst)|veratx.com - Price-to-Revenue Ratio|Dianthus Therapeutics, Inc. - P/S Multiple|Price-to-Revenue Coefficient Pharvaris NV PHVS|AbCellera Biologics Inc (ABCL) - Price-to-Revenue Ratio|Price to Sales Tourmaline (TRML)|Price-to-Revenue Ratio Precigen, Inc.|pharming.com (PHAR) - Price-to-Revenue Coefficient|P/S Multiple NKTR|Market Cap to Revenue Upstream Bio, Inc. UPB|P/S Multiple ZBIO (Zenas Biopharma, Inc.)|Price-to-Revenue Coefficient Immunome Bio (IMNM)|Gossamer Bio, Inc. - P/S Multiple|Price to Sales kalvista.com|Septerna (SEPN) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio PVLA|SVRA (Savara Corp) - P/S Multiple|Market Cap to Revenue Rigel Corp (RIGL)|P/S Multiple ANAB|ATXS - Price to Sales|Price-to-Revenue Ratio enGene ENGN|Price-to-Revenue Coefficient RAPT Therapeutics Inc. (RAPT)|JBIO: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ACRS (Aclaris Therapeutics, Inc)|KYTX: P/S Multiple|TLSA - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Cabaletta Bio|Market Cap to Revenue Ratio VTYX (Ventyx Biosciences Inc.)|P/S Multiple THTX|Market Cap to Revenue Avalo Therapeutics Inc AVTX|Eledon Pharmaceuticals - Market Cap to Revenue|Price-to-Revenue Coefficient agenusbio.com (AGEN)|Climb Bio - P/S Multiple|Price-to-Revenue Coefficient Zura Bio Ltd ZURA|ATYR: P/S Multiple|Price-to-Revenue Multiple Adagene Inc. ADAG|Price-to-Revenue Ratio ImageneBio|Market Cap to Revenue Shattuck Therapeutics (STTK)|Price-to-Revenue Ratio Equillium, Inc. (EQ)|Price-to-Revenue Coefficient connectbiopharm.com|Price-to-Revenue Ratio Immunic IMUX|ATRA (Atara Biotherapeutics, Inc.) - Price-to-Sales Ratio|InflaRx GmbH - P/S Multiple|Market Capitalization-to-Revenue Ratio XFOR (x4pharma.com)|ACET: P/S Multiple|Celularity (CELU) - P/S Multiple|Price-to-Revenue Ratio INmune Bio Corp|BRNS: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kezar Life Sciences (KZR)|Market Cap to Revenue sabbiotherapeutics.com SABS|P/S Multiple AKTX (Akari Therapeutics Plc)|P/S Multiple Enlivex Therapeutics Ltd ENLV|QTTB: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio GOVX (GeoVax Corp)|EDSA: P/S Multiple|IBIO - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Carisma Therapeutics Inc|Market Cap to Revenue XTL Biopharmaceuticals Ltd (XTLB)|Price-to-Revenue Ratio Bolt Biotherapeutics (BOLT)|Market Cap to Revenue hcwbiologics.com HCWB|Aptevo Therapeutics Inc. - Market Cap to Revenue|P/S Multiple AIM ImmunoTech, Inc. AIM|ADTX - Price-to-Revenue Ratio|GRI (GRI Bio Inc) - Market Cap to Revenue Ratio|XRTX: P/S Multiple|Price to Sales Vyome Therapeutics (HIND)|REVB (Revelation Biosciences) - P/S Multiple|indaptusrx.com (INDP) - Price-to-Revenue Coefficient|P/S Multiple SCNI|calcimedica.com (CALI) - Price-to-Revenue Multiple|Price-to-Revenue Ratio Affimed N.V. AFMD|ALLK - Market Cap to Revenue|HOOK: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ITOS (iteostherapeutics.com)|OCEA: P/S Multiple|TCBP (TC BioPharm (Holdings) Plc) - Price-to-Revenue Ratio|THRD (Third Harmonic Bio, Inc) - P/S Multiple
